Mechanistic insight of interleukin‐9 induced osteoclastogenesis
Immunology · 2023-07 · 169 (3) · 309-322
DOI: 10.1111/imm.13630 ↗At a glance
Journal article in Immunology, published online on 2023-02-15. Written by Sushmita Chakraborty and 3 co-authors. Institution: Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany. Major MEDLINE topics: Osteogenesis, Arthritis, Rheumatoid. Cited 11 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: Wellcome Trust, DBT-Wellcome Trust India Alliance, The Wellcome Trust DBT India Alliance.
Abstract (original language)
Interleukin (IL)‐9 is an emerging player in the pathogenesis of various chronic inflammatory diseases including bone disorders like rheumatoid arthritis (RA) and psoriatic arthritis. Recently, IL‐9 was shown to enhance the osteoclast formation and their function in RA. However, the mechanisms by which IL‐9 influences osteoclastogenesis are not known. Therefore, in this study we aimed to unravel the direct and indirect ways by which IL‐9 can influence osteoclast formation. We used mouse bone marrow precursor cells for checking the effect of IL‐9 on osteoclast differentiation and its function. Next, IL‐9 induced signalling pathway were checked in the process of osteoclastogenesis. T cells play an important role in enhancing osteoclastogenesis in inflammatory conditions. We used splenic T cells to understand the impact of IL‐9 on the functions of T effector (Teff) and regulatory T (Treg) cells. Furthermore, the effect of IL‐9 mediated modulation of the T cell response on osteoclasts was checked using a coculture model of T cells with osteoclast precursors. We showed that IL‐9 enhanced osteoclast formation and its function. We found that IL‐9 activates STAT3, P38 MAPK, ERK1/2, NFκB and we hypothesize that it mediates the effect on osteoclastogenesis by accelerating mitochondrial biogenesis. Additionally, IL‐9 was observed to facilitate the functions of pro‐osteoclastogenic IL‐17 producing T cells, but inhibits the function of anti‐osteoclastogenic Treg cells. Our observations suggest that IL‐9 can influence osteoclastogenesis directly by modulating the signalling cascade in the precursor cells; indirectly by enhancing IL‐17 producing T cells and by reducing the functions of Treg cells.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany.
- Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India.
ORCID profiles: Sushmita Chakraborty, Katharina F Kubatzky
Funding
- Wellcome Trust
- DBT-Wellcome Trust India Alliance
- The Wellcome Trust DBT India Alliance
Cite
APA
Chakraborty, S., Schneider, J., Mitra, D. K., & Kubatzky, K. F. (2023). Mechanistic insight of interleukin‐9 induced osteoclastogenesis. Immunology, 169(3), 309-322. https://doi.org/10.1111/imm.13630
Vancouver
Chakraborty S, Schneider J, Mitra DK, Kubatzky KF. Mechanistic insight of interleukin‐9 induced osteoclastogenesis. Immunology. 2023;169(3):309-322. doi:10.1111/imm.13630
BibTeX
@article{Chakraborty2023,
author = {Chakraborty, Sushmita and Schneider, Jakob and Mitra, Dipendra Kumar and Kubatzky, Katharina F},
title = {Mechanistic insight of interleukin‐9 induced osteoclastogenesis},
journal = {Immunology},
year = {2023},
volume = {169},
number = {3},
pages = {309--322},
doi = {10.1111/imm.13630}
}
EUVIMED